Intest Res > v.19(4)

16 results

357 Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
You Sun Kim
KMSID: 1516081304   Intest Res. 2021;19(4):357-359.   Published online 2021 October 26    DOI: http://dx.doi.org/10.5217/ir.2021.00120
      
360 Gut microbiome and checkpoint inhibitor colitis
Kanika Sehgal, Sahil Khanna
KMSID: 1516081305   Intest Res. 2021;19(4):360-364.   Published online 2020 December 1    DOI: http://dx.doi.org/10.5217/ir.2020.00116
      
365 Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
KMSID: 1516081301   Intest Res. 2021;19(4):365-378.   Published online 2020 November 25    DOI: http://dx.doi.org/10.5217/ir.2020.00097
      
379 An overview of the gut side of the SARS-CoV-2 infection
Bruna Barbosa da Luz, Natalia Mulinari Turin de Oliveira, Isabella Wzorek França dos Santos, Luana Zampieron Paza, Lara Luisa Valerio de Mello Braga, Fernanda da Silva Platner, Maria Fernanda de Paula Werner, Elizabeth Soares Fernandes, Daniele Maria-Ferreira
KMSID: 1516081300   Intest Res. 2021;19(4):379-385.   Published online 2020 November 6    DOI: http://dx.doi.org/10.5217/ir.2020.00087
      
386 Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
KMSID: 1516081299   Intest Res. 2021;19(4):386-397.   Published online 2020 December 1    DOI: http://dx.doi.org/10.5217/ir.2020.00080
      
398 Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy
KMSID: 1516081303   Intest Res. 2021;19(4):398-407.   Published online 2020 November 20    DOI: http://dx.doi.org/10.5217/ir.2020.00107
      
408 Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, Takashi Hagiwara, Takeshi Kawaberi, Haruhiko Ogata, Toshiyuki Matsui, Mamoru Watanabe, Toshifumi Hibi
KMSID: 1516081291   Intest Res. 2021;19(4):408-418.   Published online 2020 November 20    DOI: http://dx.doi.org/10.5217/ir.2020.00025
      
419 Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
KMSID: 1516081293   Intest Res. 2021;19(4):419-429.   Published online 2020 November 10    DOI: http://dx.doi.org/10.5217/ir.2020.00033
      
430 Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy
Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, Kana Onishi, Takeshi Takasago, Masaki Wakai, Toshikatsu Naito, Kensuke Sasaki, Shigehiro Doi, Takao Masaki, Kazuaki Chayama
KMSID: 1516081297   Intest Res. 2021;19(4):430-437.   Published online 2020 November 9    DOI: http://dx.doi.org/10.5217/ir.2020.00067
      
438 High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis
Saransh Jain, Divya Namdeo, Pabitra Sahu, Saurabh Kedia, Peush Sahni, Prasenjit Das, Raju Sharma, Vipin Gupta, Govind Makharia, Lalit Dar, Simon PL Travis, Vineet Ahuja
KMSID: 1516081295   Intest Res. 2021;19(4):438-447.   Published online 2020 November 6    DOI: http://dx.doi.org/10.5217/ir.2020.00055
      
448 Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi
KMSID: 1516081292   Intest Res. 2021;19(4):448-460.   Published online 2020 August 18    DOI: http://dx.doi.org/10.5217/ir.2020.00026
      
461 Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis
KMSID: 1516081296   Intest Res. 2021;19(4):461-467.   Published online 2020 August 18    DOI: http://dx.doi.org/10.5217/ir.2020.00042
      
468 Hydroxyurea associated ileocecal valve ulcer: evidence for causality
Thevaraajan Jayaraman, Ruveena Bhavani Rajaram, Gin Gin Gan, Ida Hilmi
KMSID: 1516081302   Intest Res. 2021;19(4):468-471.   Published online 2020 December 1    DOI: http://dx.doi.org/10.5217/ir.2020.00099
      
472 Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature
Eun Sil Kim, Ji Hyung Park, Yon Ho Choe, Mi Jin Kim
KMSID: 1516081298   Intest Res. 2021;19(4):472-477.   Published online 2020 October 29    DOI: http://dx.doi.org/10.5217/ir.2020.00072
      
478 Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
Jihye Park, Da Hye Kim, Soochan Kim, Hyun Woo Ma, I Seul Park, Mijeong Son, Ji Hyung Kim, Yoojin Shin, Seung Won Kim, Jae Hee Cheon
KMSID: 1516081306   Intest Res. 2021;19(4):478-481.   Published online 2021 October 26    DOI: http://dx.doi.org/10.5217/ir.2021.00121
      
482 An elderly woman with severe enteritis mimicking infectious enteritis
Kazunori Nagashima, Takashi Kato, Taichi Kimura, Kazuma Kishi, Urara Baba
KMSID: 1516081294   Intest Res. 2021;19(4):482-484.   Published online 2020 July 3    DOI: http://dx.doi.org/10.5217/ir.2020.00038
      
Articles from Intestinal Research are provided here courtesy of Korean Association for the Study of Intestinal Diseases